Durect Corporation Announces Results From Phase 2A Clinical Trial Of DUR-928 In Alcoholic Hepatitis Patients In A Late-breaking Presentation At The Liver Meeting; All Patients Treated With DUR-928 In Trial Survived 28-Day Follow-Up Period